The result of the phase 3 CHECKMATE 901 trial which looked at Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma

Opinion
Video

Dr. Sonpavde discusses the efficacy and safety findings from this randomized, open-label trial enrolling patients with advanced or metastatic urothelial carcinoma who had not received prior systemic chemotherapy.

Related Videos
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Kian-Huat Lim, MD, PhD
Nikhil Gopal, MD, assistant professor, urology, College of Medicine, Memphis Department of Urology, The University of Tennessee Health Science Center
Jonathan E. Rosenberg, MD
Benjamin Garmezy, MD
Joaquim Bellmunt, MD, PhD
Kathryn Beckermann, MD, PhD
Arlene O. Siefker-Radtke, MD
Robert Wang, MD, of Fox Chase Cancer Center
Alexander Kutikov, MD, FACS, of Fox Chase Cancer Center
Related Content
Vikram M. Narayan, MD, Emory University Hospital; director, urological oncology, Grady Memorial Hospital; assistant professor, Department of Urology, Emory University School of Medicine; member, Winship Cancer Institute

Nadofaragene Firadenovec Sets the Stage for Gene Therapies in NMIBC

May 15th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
FDA

OncLive’s April Roundup of Key FDA Decisions in Oncology

May 14th 2024
Article
Terence Friedlander, MD

FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

April 24th 2023
Podcast
Renal Cell Carcinoma - stock.adobe.com

Retrospective Data Show Metastasectomy Plus Nephrectomy Improves Survival in Non–ccRCC

May 10th 2024
Article
Joaquim Bellmunt, MD, PhD

EV-302 Trial Ushers in Era of Novel Combos in First-Line Metastatic Urothelial Cancer

May 10th 2024
Article